167 related articles for article (PubMed ID: 23422737)
1. Antitumor activity of HM781-36B, a pan-HER tyrosine kinase inhibitor, in HER2-amplified breast cancer cells.
Kim HJ; Kim HP; Yoon YK; Kim MS; Lee GS; Han SW; Im SA; Kim TY; Oh DY; Bang YJ
Anticancer Drugs; 2012 Mar; 23(3):288-97. PubMed ID: 23422737
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity of HM781-36B, an irreversible Pan-HER inhibitor, alone or in combination with cytotoxic chemotherapeutic agents in gastric cancer.
Nam HJ; Kim HP; Yoon YK; Hur HS; Song SH; Kim MS; Lee GS; Han SW; Im SA; Kim TY; Oh DY; Bang YJ
Cancer Lett; 2011 Mar; 302(2):155-65. PubMed ID: 21306821
[TBL] [Abstract][Full Text] [Related]
3. Antitumor Activity of HM781-36B, alone or in Combination with Chemotherapeutic Agents, in Colorectal Cancer Cells.
Kang MH; Moon SU; Sung JH; Kim JW; Lee KW; Lee HS; Lee JS; Kim JH
Cancer Res Treat; 2016 Jan; 48(1):355-64. PubMed ID: 25761479
[TBL] [Abstract][Full Text] [Related]
4. Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models.
Cha MY; Lee KO; Kim M; Song JY; Lee KH; Park J; Chae YJ; Kim YH; Suh KH; Lee GS; Park SB; Kim MS
Int J Cancer; 2012 May; 130(10):2445-54. PubMed ID: 21732342
[TBL] [Abstract][Full Text] [Related]
5. A small-molecule pan-HER inhibitor alone or in combination with cisplatin exerts efficacy against nasopharyngeal carcinoma.
Yang J; Yang Y; Wei Y; Wei X
Front Med; 2023 Apr; 17(2):275-289. PubMed ID: 36645632
[TBL] [Abstract][Full Text] [Related]
6. Pyrotinib Sensitizes 5-Fluorouracil-Resistant HER2
Yi J; Chen S; Yi P; Luo J; Fang M; Du Y; Zou L; Fan P
Oncol Res; 2020 Dec; 28(5):519-531. PubMed ID: 32727638
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the antitumor effects and mechanisms of PF00299804, a pan-HER inhibitor, alone or in combination with chemotherapy or targeted agents in gastric cancer.
Nam HJ; Ching KA; Kan J; Kim HP; Han SW; Im SA; Kim TY; Christensen JG; Oh DY; Bang YJ
Mol Cancer Ther; 2012 Feb; 11(2):439-51. PubMed ID: 22135232
[TBL] [Abstract][Full Text] [Related]
8. Dacomitinib (PF-00299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinib.
Kalous O; Conklin D; Desai AJ; O'Brien NA; Ginther C; Anderson L; Cohen DJ; Britten CD; Taylor I; Christensen JG; Slamon DJ; Finn RS
Mol Cancer Ther; 2012 Sep; 11(9):1978-87. PubMed ID: 22761403
[TBL] [Abstract][Full Text] [Related]
9. Positive interaction between lapatinib and capecitabine in human breast cancer models: study of molecular determinants.
Chefrour M; Milano G; Formento P; Giacometti S; Denden A; Renée N; Iliadis A; Fischel JL; Ciccolini J
Fundam Clin Pharmacol; 2012 Aug; 26(4):530-7. PubMed ID: 21623901
[TBL] [Abstract][Full Text] [Related]
10. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
Moulder SL; Yakes FM; Muthuswamy SK; Bianco R; Simpson JF; Arteaga CL
Cancer Res; 2001 Dec; 61(24):8887-95. PubMed ID: 11751413
[TBL] [Abstract][Full Text] [Related]
11. Combining AZD8931, a novel EGFR/HER2/HER3 signalling inhibitor, with AZD5363 limits AKT inhibitor induced feedback and enhances antitumour efficacy in HER2-amplified breast cancer models.
Crafter C; Vincent JP; Tang E; Dudley P; James NH; Klinowska T; Davies BR
Int J Oncol; 2015 Aug; 47(2):446-54. PubMed ID: 26095475
[TBL] [Abstract][Full Text] [Related]
12. Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy.
García-García C; Ibrahim YH; Serra V; Calvo MT; Guzmán M; Grueso J; Aura C; Pérez J; Jessen K; Liu Y; Rommel C; Tabernero J; Baselga J; Scaltriti M
Clin Cancer Res; 2012 May; 18(9):2603-12. PubMed ID: 22407832
[TBL] [Abstract][Full Text] [Related]
13. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer.
Pegram MD; Konecny GE; O'Callaghan C; Beryt M; Pietras R; Slamon DJ
J Natl Cancer Inst; 2004 May; 96(10):739-49. PubMed ID: 15150302
[TBL] [Abstract][Full Text] [Related]
14. Novel Hsp90 inhibitor FW-04-806 displays potent antitumor effects in HER2-positive breast cancer cells as a single agent or in combination with lapatinib.
Huang W; Wu QD; Zhang M; Kong YL; Cao PR; Zheng W; Xu JH; Ye M
Cancer Lett; 2015 Jan; 356(2 Pt B):862-71. PubMed ID: 25449780
[TBL] [Abstract][Full Text] [Related]
15. Ibrutinib Inhibits ERBB Receptor Tyrosine Kinases and HER2-Amplified Breast Cancer Cell Growth.
Chen J; Kinoshita T; Sukbuntherng J; Chang BY; Elias L
Mol Cancer Ther; 2016 Dec; 15(12):2835-2844. PubMed ID: 27678331
[TBL] [Abstract][Full Text] [Related]
16. Modular anti-EGFR and anti-Her2 targeting of SK-BR-3 and BT474 breast cancer cell lines in the presence of ErbB receptor-specific growth factors.
Diermeier-Daucher S; Breindl S; Buchholz S; Ortmann O; Brockhoff G
Cytometry A; 2011 Sep; 79(9):684-93. PubMed ID: 21786419
[TBL] [Abstract][Full Text] [Related]
17. The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines.
Kim JW; Kim HP; Im SA; Kang S; Hur HS; Yoon YK; Oh DY; Kim JH; Lee DS; Kim TY; Bang YJ
Cancer Lett; 2008 Dec; 272(2):296-306. PubMed ID: 18774637
[TBL] [Abstract][Full Text] [Related]
18. Lapatinib, a dual inhibitor of EGFR and HER2, has synergistic effects with 5-fluorouracil on esophageal carcinoma.
Guo XF; Zhu XF; Zhong GS; Deng BG; Gao ZT; Wang H
Oncol Rep; 2012 May; 27(5):1639-45. PubMed ID: 22293713
[TBL] [Abstract][Full Text] [Related]
19. Bruton's Tyrosine Kinase Inhibitors Prevent Therapeutic Escape in Breast Cancer Cells.
Wang X; Wong J; Sevinsky CJ; Kokabee L; Khan F; Sun Y; Conklin DS
Mol Cancer Ther; 2016 Sep; 15(9):2198-208. PubMed ID: 27256378
[TBL] [Abstract][Full Text] [Related]
20. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.
Oliveras-Ferraros C; Vazquez-Martin A; López-Bonet E; Martín-Castillo B; Del Barco S; Brunet J; Menendez JA
Int J Oncol; 2008 Dec; 33(6):1165-76. PubMed ID: 19020749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
